Daré Bioscience to Participate in Upcoming Conferences
March 02 2022 - 8:00AM
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health
innovation, today announced that members of its management team
will participate in the following conferences:
Cowen 42nd
Annual Health Care Conference
- March 7-9, 2022, Virtual
- Sabrina Martucci Johnson, President
and Chief Executive Officer, will present live on March 8, 2022 at
1:30 p.m. ET.
- Presentation webcast link:
https://wsw.com/webcast/cowen108/dare/1986732
Therapeutic Area Partnerships (TAP):
Accelerating Innovation in Women’s Health
- March 8-9, 2022, Virtual
- Sabrina Martucci Johnson, President
and CEO, will participate in and John Fair, Chief Strategy Officer,
will moderate the Solving for “X” panel on March
8, 2022 at 11:00 a.m. ET.
- Registration and additional
conference details:
https://informaconnect.com/therapeutic-area-partnerships-womens-health/
34th
Annual Roth Conference
- March 13-15, 2022, Laguna Niguel,
CA
- Sabrina Martucci Johnson, President
and CEO, will participate in the Emerging Therapies in
Women’s Health panel on March 14, 2022 at 8:00 a.m. PT.
Ms. Johnson will also provide a company presentation, available
on-demand beginning on March 11, 2022 at 5:00 a.m. PT
- Panel webcast link:
https://wsw.com/webcast/roth43/panel6/2041752
- Presentation webcast link:
https://wsw.com/webcast/roth43/dare/1801712
Archived webcasts will be available under
“Presentations, Events & Webcasts" in the Investors section of
the company's website at http://ir.darebioscience.com as
follows:
- Ms. Johnson’s
presentation at Cowen’s 42nd Annual Health Care Conference will be
available until March 22, 2022.
- The panel
discussion and Ms. Johnson’s presentation at the 34th Annual Roth
Conference will be available until March 28, 2022.
About Daré Bioscience
Daré Bioscience is a biopharmaceutical company
committed to advancing innovative products for women’s health. The
company’s mission is to identify, develop and bring to market a
diverse portfolio of differentiated therapies that prioritize
women's health and well-being, expand treatment options, and
improve outcomes, primarily in the areas of contraception,
fertility, and vaginal and sexual health.
Daré’s first FDA-approved product, XACIATOTM
(clindamycin phosphate), is a lincosamide antibacterial indicated
for the treatment of bacterial vaginosis in female patients 12
years of age and older. XACIATO is a clear, colorless, viscous gel,
to be administered once intravaginally as a single dose. Daré’s
product portfolio also includes potential first-in-category
candidates in clinical development: Ovaprene®, a novel,
hormone-free monthly contraceptive whose U.S. commercial
rights are under a license agreement with Bayer; Sildenafil Cream,
3.6%, a novel cream formulation of sildenafil to treat female
sexual arousal disorder utilizing the active ingredient in Viagra®;
and DARE-HRT1, a combination bio-identical estradiol and
progesterone intravaginal ring for hormone therapy following
menopause. To learn more about XACIATOTM, Daré’s full portfolio of
women’s health product candidates, and Daré’s mission to deliver
differentiated therapies for women, please
visit www.darebioscience.com.
Daré may announce material information about its
finances, product and product candidates, clinical trials and other
matters using the Investors section of its website
(http://ir.darebioscience.com), SEC filings, press
releases, public conference calls and webcasts. Daré will use these
channels to distribute material information about the company, and
may also use social media to communicate important information
about the company, its finances, product and product candidates,
clinical trials and other matters. The information Daré posts on
its investor relations website or through social media channels may
be deemed to be material information. Daré encourages investors,
the media, and others interested in the company to review the
information Daré posts in the Investors section of its website and
to follow these Twitter accounts: @SabrinaDareCEO and
@DareBioscience. Any updates to the list of social media channels
the company may use to communicate information will be posted in
the Investors section of Daré’s website.
Contacts:
Investors on behalf of Daré Bioscience, Inc.:Lee Roth Burns
McClellanlroth@burnsmc.com212.213.0006
OR
Media on behalf of Daré Bioscience, Inc.:Jake RobisonCanale
Communicationsjake.robison@canalecomm.com 619.849.5383
Source: Daré Bioscience, Inc.
Dare Bioscience (NASDAQ:DARE)
Historical Stock Chart
From Jun 2024 to Jul 2024
Dare Bioscience (NASDAQ:DARE)
Historical Stock Chart
From Jul 2023 to Jul 2024